Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Vanguard Ultra Short Bond ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VUSB | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $50.03 |
52-Week Low | $2.84 | $49.60 |
Enterprise Value | $946.50M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
